Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference
September 08 2021 - 4:05PM
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision
oncology company developing next-generation therapies that target
genetic drivers of cancer, today announced a late-breaker abstract
of early clinical data by physician assessment for repotrectinib in
NTRK-positive TKI-naïve and TKI-pretreated advanced solid tumor
cohorts of TRIDENT-1 has been accepted for oral presentation in a
plenary session at the Virtual International Conference on
Molecular Targets and Cancer Therapeutics hosted by the American
Association for Cancer Research (AACR), the National Cancer
Institute (NCI) and the European Organisation for Research and
Treatment of Cancer (EORTC) on Oct. 7-10.
In addition to the late-breaker abstract, two additional
abstracts have been selected for presentation at the meeting:
- Repotrectinib clinical data by physician assessment from the
ROS1-positive non-small cell lung cancer TKI-pretreated cohorts
(EXP-2, EXP-3 and EXP-4) of TRIDENT-1; and
- TPX-0022 clinical data by physician assessment from the Phase 1
dose finding portion of SHIELD-1 in patients with advanced solid
tumors harboring genetic alterations in MET.
About Turning Point Therapeutics
Inc.Turning Point Therapeutics is a clinical-stage
precision oncology company with a pipeline of internally discovered
investigational drugs designed to address key limitations of
existing cancer therapies. The company’s lead drug candidate,
repotrectinib, is a next-generation kinase inhibitor targeting the
ROS1 and TRK oncogenic drivers of non-small cell lung cancer and
advanced solid tumors. Repotrectinib, which is being studied in a
registrational Phase 2 study in adults and a Phase 1/2 study in
pediatric patients, has shown antitumor activity and durable
responses among kinase inhibitor treatment-naïve and pre-treated
patients. The company’s pipeline of drug candidates also includes
TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a
Phase 1 trial of patients with advanced or metastatic solid tumors
harboring genetic alterations in MET; TPX-0046, targeting RET,
which is being studied in a Phase 1/2 trial of patients with
advanced or metastatic solid tumors harboring genetic alterations
in RET; and TPX-0131, a next-generation ALK inhibitor, which is
being studied in a Phase 1/2 trial of previously treated patients
with ALK-positive advanced or metastatic non-small cell lung
cancer. Turning Point’s next-generation kinase inhibitors are
designed to bind to their targets with greater precision and
affinity than existing therapies, with a novel, compact structure
that has demonstrated an ability to potentially overcome treatment
resistance common with other kinase inhibitors. The company is
driven to develop therapies that mark a turning point for patients
in their cancer treatment. For more information,
visit www.tptherapeutics.com.
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Words such as “plans”, “will”,
“believes,” “anticipates,” “expects,” “intends,” “goal,”
“potential” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based upon Turning Point Therapeutics’ current expectations and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
risks and uncertainties associated with Turning Point Therapeutics’
business in general, risks and uncertainties related to the impact
of the COVID-19 pandemic to Turning Point’s business and the other
risks described in Turning Point Therapeutics’ filings with
the SEC, including its quarterly report on Form 10-Q filed
with the SEC on August 9, 2021. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Turning Point
Therapeutics undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Contact: Scott Lipman
ir@tptherapeutics.com 858-876-3985
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Sep 2023 to Sep 2024